Format

Send to

Choose Destination
Rheumatology (Oxford). 2018 Jun 1;57(6):951-958. doi: 10.1093/rheumatology/kex343.

Recent pharmacological advances in the management of gout.

Author information

1
Faculty of Health and Medicine, Lancaster University, Lancaster, UK.
2
Department of Rheumatology, University Hospitals of Morecambe Bay NHS Foundation Trust, Royal Lancaster Infirmary, Lancaster, UK.

Abstract

Gout is the most common cause of inflammatory arthritis worldwide, and reports show that despite availability of therapies, management is still suboptimal. The new EULAR 2016 recommendations for the treatment of gout highlight the huge development in gout therapies, and the number of drugs being trialled only continues to increase. A clinical review of the evidence that underlies the recommendations from EULAR can reveal possible gaps in the literature and avenues for future research into gout therapies.

PMID:
28968896
DOI:
10.1093/rheumatology/kex343
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Silverchair Information Systems
Loading ...
Support Center